Passage Bio, Inc. (PASG) Investor Relations Documents

Passage Bio, Inc. (PASG) investor relations documents from the company's IR site: 3 presentations, 37 press releases; latest deck 2026-05-11. Read in-app with summaries. First-party data.

Download PDF (opens in new window): Passage Bio is developing PBFT02, a one-time gene therapy for FTD-GRN, which has demonstrated robust, durable increases in CSF progranulin levels in clinical trials.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-06-24Press releasePassage Bio and Remix Therapeutics Announce Merger Agreement
2026-06-24Press releasePassage Bio and Remix Therapeutics Announce Merger Agreement
2026-05-11PresentationDownload PDF (opens in new window)
2026-04-20Press releasePassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
2026-04-20Press releasePassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
2026-03-03Press releasePassage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
2026-02-19Press releasePassage Bio to Participate in Upcoming Investor Conferences
2025-11-10Press releasePassage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
2025-11-05Press releasePassage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
2025-08-28Press releasePassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
2025-08-12Press releasePassage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
2025-07-10Press releasePassage Bio Announces 1-for-20 Reverse Stock Split
2025-06-23Press releasePassage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
2025-05-13Press releasePassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
2025-05-09PresentationASGCT Poster: Scalable Production of an AAV Manufacturing Platform - Transitioning from Adherent to Suspension-Based Tri
2025-04-03PresentationAD/PD™ 2025 International Conference
2025-03-04Press releasePassage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
2025-03-04Press releasePress Release
2025-02-26Press releasePassage Bio to Participate in Upcoming Investor Conferences
2025-01-10Press releasePassage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
2024-11-13Press releasePassage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
2024-11-13Press releasePress Release
2024-11-06Press releasePassage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
2024-10-24Press releasePassage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell
2024-09-23Press releasePassage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
2024-09-16Press releasePassage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International
2024-09-10Press releasePassage Bio Welcomes Tom Kassberg to Board of Directors
2024-08-30Press releasePassage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
2024-08-08Press releasePassage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
2024-08-08Press releasePress Release
2024-08-06Press releasePassage Bio to Participate in Upcoming Investor Conferences
2024-08-01Press releasePassage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collabor
2024-07-16Press releasePassage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patient
2024-06-05Press releasePassage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-21Press releasePassage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
2024-05-14Press releasePassage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
2024-05-14Press releasePress Release
2024-04-22Press releasePassage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
2024-03-05Press releasePassage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
2024-03-04Press releasePassage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

PASG overview · PASG earnings · PASG financials · PASG KPIs · PASG ownership · PASG peers · PASG filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.